Trokendi Xr Capsule, Extended Release
Product Images NDC 17772-102

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trokendi Xr (NDC 17772-102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Supernus Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Trokendi 01)

Chemical structure diagram of the active ingredient topiramate, shown with molecular bonds and functional groups in a planar format.*

FDA Label Image

Figure 1 (Trokendi 02)

A Kaplan-Meier survival curve chart comparing cumulative rates of time to first seizure in patients taking topiramate at 50 mg/day versus 400 mg/day. The x-axis represents time in days, and the y-axis shows cumulative seizure rates. The graph presents data sets for N=234 and N=236 patients respectively and includes a p-value indicating statistical comparison.*

FDA Label Image

Figure 2 (Trokendi 03)

A bar chart comparing changes from baseline to the double-blind phase in average monthly migraine period rate for placebo, topiramate 50 mg/day, 100 mg/day, and 200 mg/day groups. Results from two studies are shown with different bar styles, indicating greater reductions in migraine rates with increasing topiramate dose compared to placebo.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Label for Trokendi XR 25 mg extended-release capsules, each capsule containing topiramate. The label specifies a light green opaque body with a yellow opaque cap and a 30-capsule count. Manufactured by Catalent Pharma Solutions and marketed by Supernus Pharmaceuticals, Inc. The label includes dosing instructions to swallow the capsule whole, storage guidelines, a barcode, and the NDC 17772-101-30.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Label for Trokendi XR 50 mg extended-release capsules, containing 30 capsules per bottle. The capsule is described as having a light green opaque body and an orange opaque cap. The label includes directions to take once daily and instructions to swallow the capsule whole and intact. The product is labeled for prescription use only and is manufactured for Supernus Pharmaceuticals, Inc.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

Label for Trokendi XR 100 mg extended-release capsules by Supernus Pharmaceuticals, Inc. Capsule described as having green opaque body and blue opaque cap. The label includes dosing instructions as once daily, with a warning to swallow capsule whole and not to open or crush. Package contains 30 capsules. Storage instructions and manufacturer information are also included.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Trokendi XR 200 mg extended-release capsules packaging label by Supernus Pharmaceuticals, Inc. The label specifies the dosage form as a capsule with a pink opaque body and blue opaque cap. The package contains 30 capsules, designed for once-daily oral use. The label includes instructions to swallow capsules whole and intact and cautions against opening, crushing, chewing, or sprinkling capsule contents on food. Storage and manufacturing information is also provided.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.